APOG

Apogee Enterprises

Fundamental data last updated:April 13, 2026

company profile

SECTOR

Industrials

industry

Building Products & Equipment

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

04/24/26

Business Summary

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic cell therapies, primarily in oncology. Its model revolves around advancing engineered cell therapy candidates through clinical trials with the goal of eventual regulatory approval and commercialization or strategic partnerships. Cash generation is currently absent; value creation depends on successful trial outcomes that unlock licensing deals, milestone payments, or future product revenues. Its potential moat lies in proprietary cell therapy platforms, manufacturing know-how, and intellectual property around engineered immune cells—assets that, if validated clinically, could create high switching costs and differentiated therapeutic positioning.

VALUATION

P/E

19.4

Market Cap ($M USD)

$779

Forward P/E

11.9

PEG

1.1

PRICE TO SALES

0.6

PRICE TO BOOK

1.5

EV / EBITDA

8.50

5-Year Average P/E

DIVIDEND

Yield

2.90%

Annual Payout

$1.08

Payout Ratio

55.30%

Consecutive Years of Dividend Growth

10+

5-Year Dividend Growth Rate

6.20%

Financial Health & Profitability

Earnings Per Share

$1.88

Next Year EPS Growth Estimate

$3.06

Next Year Revenue Growth Estimate

-2.00%

Return on Equity (ROE)

7.80%

Operating Margin

4.60%

Debt-to-Equity

0.6

Piotroski F-Score

7

Altman Z-Score

2.90

Return on Invested Capital (ROIC)

6.60%%

Current Ratio

1.9

Quick Ratio

Gainseekers Quantitative Analysis

Summary

This is a highly speculative, distressed biotechnology name masquerading as an equity investment. With no P/E, no Forward P/E, a deeply negative EPS of -2.8, and an Altman Z-Score of -4.5, the balance sheet signals material financial stress and potential solvency risk. Operating Margin at -65.20% and ROIC at -47.10% confirm capital destruction at scale. A Piotroski F-Score of 2 reinforces fundamental weakness. At a $663M market cap and a Price/Book of 2.3, the market is not pricing in stability or profitability—this is a binary outcome vehicle, not a compounding machine.

AI Exposure / Tech Reliance

As a biotechnology company in Healthcare, ALLO operates in one of the most AI-leveraged segments of the market, where computational biology, data modeling, and precision targeting are increasingly core to R&D efficiency. The sector’s shift toward AI-driven drug discovery could enhance pipeline productivity, but that benefit is industry-wide and not company-specific. Given its current financial fragility, technology leverage alone will not offset operational cash burn.

The Bull Case

A deep value investor could argue that the Current Ratio of 7.9 indicates substantial short-term liquidity, providing runway to advance its programs without immediate balance sheet strain. Despite a weak Piotroski F-Score of 2, the extremely depressed profitability metrics and negative EPS of -2.8 set a low bar for operational improvement; even modest clinical or cost progress could materially re-rate the equity. The $663M market cap in biotech terms is relatively small, meaning any positive inflection in earnings expectations (EPS Next Year estimated at -$0.87 versus -2.8 currently) could represent a dramatic trajectory shift. In pure optionality terms, this is priced as distressed science rather than a functioning growth platform, which is exactly where asymmetric biotech returns occasionally originate.

The Bear Case

The bear case is overwhelming. An Altman Z-Score of -4.5 is not just weak—it is distress territory. Operating Margin of -65.20% and ROIC of -47.10% show that every dollar invested is being structurally eroded, and there is no evidence of operating leverage. No P/E, no Forward P/E, and no PEG signal the absence of earnings visibility, while a Piotroski F-Score of 2 suggests deteriorating financial strength. This is a cash-burning biotech with negative earnings, no profitability metrics to anchor valuation, and clear financial fragility—precisely the profile that leads to dilution risk and permanent capital impairment.

Market Sentiment & Smart Money

Short Interest %

4.80%

Analyst Consensus

1.83

Average Analyst Price Target

$52.50

Institutional Ownership %

96.60%

1-Year Beta

0.99

Insider Buying % (6 Mo)

2.30%%

Distance to 52-Week High

72.50%%

Distance to 52-Week Low

117.80%%